Efzimfotase alfa
Efzimfotase alfa (ALXN-1850) is enzyme replacement therapy agent targeting the deficiency of tissue-nonspecific alkaline phosphatase (TNSALP) . Efzimfotase alfa functions by hydrolyzing the substrates of TNSALP, reducing the concentrations of substrates such as inorganic pyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP) . Efzimfotase alfa is promising for research of hypophosphatasia (HPP) [1][2].
Product Specifications
CAS Number
[2746354-58-3]
Product Name Alternative
ALXN-1850
UNSPSC
12352203
Target
Phosphatase
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Smiles
[Efzimfotasealfa]
References & Citations
[1]Dahir KM, et al. Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa. Curr Osteoporos Rep. 2025 Mar 18;23 (1) :14.|[2]Dahir KM, et al. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. J Bone Miner Res. 2024 Sep 26;39 (10) :1412-1423.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
